Biocancell Therapeutics Ltd. (TASE:BICL) today reported successful results in the preclinical animal trial of BC-821 next-generation drug for treatment of brain cancer.
The trial was conducted by Dr. Doron Amit of Hebrew University of Jerusalem and BioCancell chief scientist Prof. Avraham Hochberg. The study found that there were material delays in the development of Glioblastoma multiforme primary brain cancer tumors in 60% of the rats in the study.
BioCancell believes that the results are a positive indication of BC-821's effectiveness for treating primary brain tumors in people. On the basis of the results, the company will review continuing development of the drug on cancers expressed by high levels of the IGF2 gene and the conduct of animal trials for these types of cancers. The company will use its own resources for these trials.
BioCancell's leading drug candidate, BC-819 was found safe and effective in a Phase I/IIa clinical trial for the treatment of pancreatic cancer, and is undergoing a Phase IIb trial for bladder cancer and Phase I/IIa trial for pancreatic cancer.
Biocancell's share price rose 2.2% in morning trading to NIS 2.60, giving a market cap of NIS 70 million.
Published by Globes [online], Israel business news - www.globes-online.com - on December 21, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010